テクリスタマブで治療された不治性多発性骨髄腫の若い患者の透析独立:症例報告
Ioannis Ntanasis-Stathopoulos1, Ilias Katsadouros1, Panagiotis Malandrakis1
1Plasma Cell Dyscrasias Unit, Department of Clinical Therapeutics, Alexandra General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.
Oncology letters
|August 22, 2025
まとめ
Teclistamabは重発した/ 耐性多発性骨髄腫の治療に有効であり,重度の腎臓疾患の患者でも有効である. この双特定抗体は,末期性腎疾患の患者において,疾患の寛解と腎機能の改善をもたらした.
科学分野:
- 腫瘍学
- 免疫療法
- 腎臓科
背景:
- 再発性/耐性多発性骨髄腫 (RRMM) は,特に腎機能不全の患者において,治療に重大な課題をもたらします.
- 既存の治療法は,重度の腎機能不全の患者では,しばしば有効性が限られているか,または禁忌である.
さらに関連する動画
関連する概念動画
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K

![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
